Dr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the ...

Dr Reddy’s Laboratories on Thursday said its subsidiary has inked a licence agreement with Shanghai Henlius Biotech, Inc to develop and commercialise an under-development cancer drug. Dr Reddy’s ...

Dr. Reddy’s to develop and commercialize biosimilar candidate for Johnson & Johnson’s Darzalex drugs with Shanghai Henlius Biotech.

Dr Reddy’s Laboratories has signed a license deal with Shanghai Henlius Biotech to develop and market HLX15, an investigational cancer drug. Henlius will handle development and manufacturing, ...

Synthetic biologists from Yale were able to re-write the genetic code of an organism—a novel genomically recoded organism ...

HYDERABAD: Dr Reddy’s Laboratories SA, the wholly-owned Swiss subsidiary of Hyderabad-based pharma biggie Dr Reddy’s ...

Trinity Biotech ( ($TRIB) ) has shared an update. On February 6, 2025, Trinity Biotech announced significant improvements in its continuous ...

VANCOUVER, Washington, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a ...

The search for new tuberculosis drug targets under traditional laboratory methods has historically proven to be arduous and ...

E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, ...

Crown Laboratories and its affiliate Reba Merger Sub will now pay for the shares, which will cost the company $314.6 million.